Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma
Purpose Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals. Methods We reviewed literature in terms of liver transplant criteria for hepatocellular car...
Gespeichert in:
| Veröffentlicht in: | Journal of gastrointestinal cancer 2020-12, Vol.51 (4), p.1118-1121 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1121 |
|---|---|
| container_issue | 4 |
| container_start_page | 1118 |
| container_title | Journal of gastrointestinal cancer |
| container_volume | 51 |
| creator | Ince, Volkan Ara, Cengiz Yilmaz, Sezai |
| description | Purpose
Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.
Methods
We reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.
Results
The Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.
Conclusion
It is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%. |
| doi_str_mv | 10.1007/s12029-020-00484-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2438677573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438677573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-f700cd36f26c1f37c31ccec6c1d60468aacb43563ae167206bd6e3230b2a0a493</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EoqXwBRhQRpbA-U-cdEQVUKSiMpTZujgOpEqdYCdI-fa4pHRkujvfe0_nHyHXFO4oQHrvKQM2j4FBDCAyEQ8nZErngsZScnl67Fk2IRfebwGkSCg9JxPOMgmSJlPy9oo1dgNGaIto3X0aFy1c1RlXYVQ2LlpV3-Fp49D6tkbbYVc1NqpstDQtdo02dd3XGEzodGWbHV6SsxJrb64OdUbenx43i2W8Wj-_LB5WseYi7eIyBdAFlyWTmpY81ZxqbXQYCglCZog6FzyRHA2VKQOZF9JwxiFnCCjmfEZux9zWNV-98Z3aVX5_DlrT9F4xwTOZpknKg5SNUu0a750pVeuqHbpBUVB7kmokqQJJ9UtSDcF0c8jv850pjpY_dEHAR4EPK_thnNo2vbPhz__F_gCJsH8-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2438677573</pqid></control><display><type>article</type><title>Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ince, Volkan ; Ara, Cengiz ; Yilmaz, Sezai</creator><creatorcontrib>Ince, Volkan ; Ara, Cengiz ; Yilmaz, Sezai</creatorcontrib><description>Purpose
Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.
Methods
We reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.
Results
The Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.
Conclusion
It is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%.</description><identifier>ISSN: 1941-6628</identifier><identifier>EISSN: 1941-6636</identifier><identifier>DOI: 10.1007/s12029-020-00484-y</identifier><identifier>PMID: 32860615</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers, Tumor - analysis ; Cancer Research ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Gastroenterology ; Humans ; Internal Medicine ; Liver - pathology ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - mortality ; Liver Cirrhosis - pathology ; Liver Cirrhosis - surgery ; Liver Neoplasms - diagnosis ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Liver Transplantation - standards ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - epidemiology ; Oncology ; Patient Selection ; Radiotherapy ; Review Article ; Risk Assessment - methods ; Survival Rate ; Tumor Burden</subject><ispartof>Journal of gastrointestinal cancer, 2020-12, Vol.51 (4), p.1118-1121</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-f700cd36f26c1f37c31ccec6c1d60468aacb43563ae167206bd6e3230b2a0a493</citedby><cites>FETCH-LOGICAL-c347t-f700cd36f26c1f37c31ccec6c1d60468aacb43563ae167206bd6e3230b2a0a493</cites><orcidid>0000-0002-6843-875X ; 0000-0002-0714-490X ; 0000-0002-8044-0297</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12029-020-00484-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12029-020-00484-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32860615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ince, Volkan</creatorcontrib><creatorcontrib>Ara, Cengiz</creatorcontrib><creatorcontrib>Yilmaz, Sezai</creatorcontrib><title>Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma</title><title>Journal of gastrointestinal cancer</title><addtitle>J Gastrointest Canc</addtitle><addtitle>J Gastrointest Cancer</addtitle><description>Purpose
Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.
Methods
We reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.
Results
The Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.
Conclusion
It is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%.</description><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - surgery</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver Transplantation - standards</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Oncology</subject><subject>Patient Selection</subject><subject>Radiotherapy</subject><subject>Review Article</subject><subject>Risk Assessment - methods</subject><subject>Survival Rate</subject><subject>Tumor Burden</subject><issn>1941-6628</issn><issn>1941-6636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EoqXwBRhQRpbA-U-cdEQVUKSiMpTZujgOpEqdYCdI-fa4pHRkujvfe0_nHyHXFO4oQHrvKQM2j4FBDCAyEQ8nZErngsZScnl67Fk2IRfebwGkSCg9JxPOMgmSJlPy9oo1dgNGaIto3X0aFy1c1RlXYVQ2LlpV3-Fp49D6tkbbYVc1NqpstDQtdo02dd3XGEzodGWbHV6SsxJrb64OdUbenx43i2W8Wj-_LB5WseYi7eIyBdAFlyWTmpY81ZxqbXQYCglCZog6FzyRHA2VKQOZF9JwxiFnCCjmfEZux9zWNV-98Z3aVX5_DlrT9F4xwTOZpknKg5SNUu0a750pVeuqHbpBUVB7kmokqQJJ9UtSDcF0c8jv850pjpY_dEHAR4EPK_thnNo2vbPhz__F_gCJsH8-</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Ince, Volkan</creator><creator>Ara, Cengiz</creator><creator>Yilmaz, Sezai</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6843-875X</orcidid><orcidid>https://orcid.org/0000-0002-0714-490X</orcidid><orcidid>https://orcid.org/0000-0002-8044-0297</orcidid></search><sort><creationdate>20201201</creationdate><title>Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma</title><author>Ince, Volkan ; Ara, Cengiz ; Yilmaz, Sezai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-f700cd36f26c1f37c31ccec6c1d60468aacb43563ae167206bd6e3230b2a0a493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - surgery</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver Transplantation - standards</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Oncology</topic><topic>Patient Selection</topic><topic>Radiotherapy</topic><topic>Review Article</topic><topic>Risk Assessment - methods</topic><topic>Survival Rate</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ince, Volkan</creatorcontrib><creatorcontrib>Ara, Cengiz</creatorcontrib><creatorcontrib>Yilmaz, Sezai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ince, Volkan</au><au>Ara, Cengiz</au><au>Yilmaz, Sezai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma</atitle><jtitle>Journal of gastrointestinal cancer</jtitle><stitle>J Gastrointest Canc</stitle><addtitle>J Gastrointest Cancer</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>51</volume><issue>4</issue><spage>1118</spage><epage>1121</epage><pages>1118-1121</pages><issn>1941-6628</issn><eissn>1941-6636</eissn><abstract>Purpose
Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.
Methods
We reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.
Results
The Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.
Conclusion
It is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32860615</pmid><doi>10.1007/s12029-020-00484-y</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6843-875X</orcidid><orcidid>https://orcid.org/0000-0002-0714-490X</orcidid><orcidid>https://orcid.org/0000-0002-8044-0297</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-6628 |
| ispartof | Journal of gastrointestinal cancer, 2020-12, Vol.51 (4), p.1118-1121 |
| issn | 1941-6628 1941-6636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2438677573 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biomarkers, Tumor - analysis Cancer Research Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Gastroenterology Humans Internal Medicine Liver - pathology Liver Cirrhosis - diagnosis Liver Cirrhosis - mortality Liver Cirrhosis - pathology Liver Cirrhosis - surgery Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Liver Transplantation - standards Medicine Medicine & Public Health Neoplasm Recurrence, Local - epidemiology Oncology Patient Selection Radiotherapy Review Article Risk Assessment - methods Survival Rate Tumor Burden |
| title | Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A41%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malatya%20and%20Other%20Criteria%20for%20Liver%20Transplantation%20in%20Hepatocellular%20Carcinoma&rft.jtitle=Journal%20of%20gastrointestinal%20cancer&rft.au=Ince,%20Volkan&rft.date=2020-12-01&rft.volume=51&rft.issue=4&rft.spage=1118&rft.epage=1121&rft.pages=1118-1121&rft.issn=1941-6628&rft.eissn=1941-6636&rft_id=info:doi/10.1007/s12029-020-00484-y&rft_dat=%3Cproquest_cross%3E2438677573%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2438677573&rft_id=info:pmid/32860615&rfr_iscdi=true |